Corporate Profile  

Target Market 
 

Business Strategy
Our Story

Mission Statement

Officers & Key Personnel

Scientific Advisory Board

 

   
Kenneth A. Thomas, Ph.D.  
  Dr. Thomas

Vice President, Research and Development

Dr. Thomas brings to CVBT over two decades of experience at the Merck Research Laboratories in scientific research and pharmaceutical development of therapeutic proteins and small molecule enzyme inhibitors.  His scientific and managerial expertise includes the areas of biological chemistry, molecular biology, cell biology and animal pharmacology spanning cardiology, endocrinology, dermatology, ophthalmology and oncology.  He has served on The Journal of Biological Chemistry editorial board, co-organized national and international meetings on growth factors, angiogenesis, protein kinases and signal transduction, and has over 90 publications and 40 issued patents.

While at Merck, Dr. Thomas initiated, built and directed the preclinical biology programs leading to six angiogenic and anti-angiogenic development candidates.  This work was based on his initial discovery and characterization of FGF-1 and research on functionally related angiogenic growth factors and their receptors. 

Dr. Thomas received a B.S. degree in Chemistry from the University of Delaware and a Ph.D. in Biochemistry from Duke University followed by postdoctoral fellowships at the National Institutes of Health and Washington University in St. Louis.

< Back to Scientists

< Back to Officers & Key Personnel

 

 

 

 

Use of this site constitutes agreement to our Terms and Conditions
and Privacy Policy. Site Design and Contents © 2008 CardioVascular BioTherapeutics, Inc. All Rights Reserved.

Some content on this site requires the free Adobe Reader.

 

12/11/2008
CVBT Opens Two Additional Sites for Patient Enrollment for Phase II Heart Trial


11/25/2008
CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease


11/13/2008
CVBT Closes Clinical Development Agreement for Coronary Heart Disease Drug Candidate


9/9/2008
CVBT Announces First Site to Begin Patient Enrollment for Its Phase II Heart Trial